Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
08/17 CYTOKINETICS : CK-107 Muscles In at Phase 2
08/11 INSIDER TRADING ACTIVITY CYTOKINETIC : CYTK) – Insider Sold 11,348 shares ..
08/04 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
08/04 CYTOKINETICS, INC. : Featured Company News - Cytokinetics Announces Positive Res..
08/03 CYTOKINETICS : Announces Positive Results From Phase 2 Clinical Trial of Omecamt..
08/03 INSIDER TRADING ACTIVITY CYTOKINETIC : CYTK) – CEO Sold 5,000 shares of St..
08/02 CYTOKINETICS : reports 2Q loss
08/02 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Results of Operations an..
08/02 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
08/02 Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results
More news
Financials ($)
Sales 2017 20,7 M
EBIT 2017 -106 M
Net income 2017 -102 M
Finance 2017 191 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 23,3x
EV / Sales 2018 12,2x
Capitalization 674 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,9 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.674
AMGEN16.32%124 096
CELGENE CORPORATION10.09%101 932
GILEAD SCIENCES0.70%95 777
REGENERON PHARMACEUTICALS27.48%51 288
VERTEX PHARMACEUTICALS111.05%39 199